• Facebook
  • Twitter
  • Instagram
  • Login/Register
  • Terms & Conditions
  • About
  • Expert Panel
  • Contact Us
MYELOMA360
  • Home
  • News
  • Education
    • Conference Coverage
      • ASCO & EHA 2019
      • EHA 2018
      • ASH 2017
    • CME & Webcasts
  • Events
  • Resources
    • Practice Resources
    • Patient Information
      • Product Education
      • Books
  • Videos
Select Page

Real-life experience with plasmapheresis in newly diagnosed multiple myeloma accompanied by acute kidney injury

by | Sep 28, 2023 | Publications

Ir J Med Sci. 2023 Sep 28. doi: 10.1007/s11845-023-03535-y. Online ahead of print. ABSTRACT OBJECTIVES: The aim of this study was to retrospectively evaluate the effect of plasmapheresis treatment concomitant with chemotherapy and the number of sessions on renal...

A Fully Human IgE Specific for CD38 as a Potential Therapy for Multiple Myeloma

by | Sep 28, 2023 | Publications

Cancers (Basel). 2023 Sep 13;15(18):4533. doi: 10.3390/cancers15184533. ABSTRACT Multiple myeloma (MM) is an incurable malignancy of plasma cells and the second most common hematologic malignancy in the United States. Although antibodies in clinical cancer therapy are...

Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial

by | Sep 28, 2023 | Publications

Cancers (Basel). 2023 Sep 21;15(18):4667. doi: 10.3390/cancers15184667. ABSTRACT Renal function impairment (RI) is a common complication in multiple myeloma (MM). However, limited data exist on the safety and efficacy of anti-MM regimens in patients with severe RI, as...

Lenalidomide Promotes Thrombosis Formation, but Does Not Affect Platelet Activation in Multiple Myeloma

by | Sep 28, 2023 | Publications

Int J Mol Sci. 2023 Sep 14;24(18):14097. doi: 10.3390/ijms241814097. ABSTRACT Lenalidomide, a well-established drug for the treatment of multiple myeloma, significantly enhances patients’ survival. Previous clinical studies have demonstrated that its main side...

Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure

by | Sep 28, 2023 | Publications

Life (Basel). 2023 Aug 31;13(9):1841. doi: 10.3390/life13091841. ABSTRACT Anti-CD38 monoclonal antibody (MoAB) therapy has significantly improved the prognosis of patients with multiple myeloma. However, not all patients sustain durable responses. We aimed to describe...

Experience of Autologous Stem Cell Transplant in Multiple Myeloma: The Patient and Caregiver Perspective

by | Sep 28, 2023 | Publications

J Patient Exp. 2023 Sep 25;10:23743735231202733. doi: 10.1177/23743735231202733. eCollection 2023. ABSTRACT A qualitative study of the experiences of patients who received autologous stem cell transplant (ASCT) for the treatment of multiple myeloma (MM) was conducted...
« Older Entries

Recent Content

  • Systemic Review Sheds Light on Efficacy of Bispecific Antibodies in Extramedullary R/R Multiple Myeloma
  • Real-life experience with plasmapheresis in newly diagnosed multiple myeloma accompanied by acute kidney injury
  • Health care professionals express support for postpartum depression, myeloma treatments
  • Physical Activity Improves Performance, Frailty Scores, and PROs in Multiple Myeloma
  • Limited Efficacy Seen With Ixazomib Plus Daratumumab and Low-Dose Dexamethasone in Intermediate-Fit Patients With MM
  • Dr Beksac on OS Data From the OPTIMISMM Trial in Relapsed/Refractory Multiple Myeloma
  • Dr Leypoldt on the Use of Isa-KRd in Newly Diagnosed, High-Risk Multiple Myeloma
  • A Fully Human IgE Specific for CD38 as a Potential Therapy for Multiple Myeloma
  • Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
  • Lenalidomide Promotes Thrombosis Formation, but Does Not Affect Platelet Activation in Multiple Myeloma
  • Login/Register
  • Terms & Conditions
  • About
  • Expert Panel
  • Contact Us
  • Facebook
  • Twitter
  • Instagram
©2016-2023 MYELOMA360 & MindWrap Medical, LLC
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT